Agilent sells Hycor Biomedical to Linden

Agilent has announced the sale of Hycor Biomedical, a firm that has been acquired by healthcare firm Linden.

Hycor Biomedical constituted part of Agilent’s deal to purchase Stratagene in 2007. The company specialises in the manufacturing, developing and marketing of invitro diagnostic products for the global allergy, autoimmune and urinalysis markets.

The terms of Linden and Agilent’s agreement have not yet been disclosed.

Nick Roelofs, president of Agilent’s life sciences group, said that Hycor Biomedical’s potential spans beyond Agilent’s portfolio, adding that he is pleased that Linden will be able to utilise its assets to their full potential.

He explained: “Hycor is an innovative, profitable and growing business, but it does not fit the core focus of our life science business.”

This news comes after Agilent was granted conditional antitrust clearance from the European Commission last month, regarding its proposed acquisition of Varian.

The two firms will now collaborate to sell the latter company’s laboratory gas chromatography business and its triple quadrupole gas chromatography-mass spectrometry operations.